Podcasts about biomarin

The turbulence that has come with the Trump administration's policies related to the U.S. biopharmaceutical industry is creating an opening for Europe to bolster its life sciences industry. On the latest BioCentury This Week podcast, BioCentury's editors look at how Europe can capitalize on staffing cuts at FDA and NIH and an uncertain policy environment to lure back talent to bolster regulatory agencies and biotech R&D engines and attract assets and partners from China.The editors also discuss two biotech deals driven by former leaders of BD at Roche, Biomarin's James Sabry and Sophie Kornowski at Boston Pharmaceuticals. Under the leadership of Sabry and CEO Alexander Hardy, Biomarin delivered its first takeout in a decade by acquiring Inozyme as it positions itself to take advantage of a regulatory and policy environment that they believe is favorable to their rare disease strategy. CEO Kornowski, meanwhile, executed on a plan to focus her company on a single liver disease asset that GSK acquired for $1.2 billion up front. Finally, BioCentury's editors discuss the management shake-up at obesity company Novo Nordisk, where Lars Fruergaard Jørgensen, the leader who spearheaded Novo Nordisk's transformation into a dominant player in obesity, is stepping down.Chan Zuckerberg Chicago Biohub is hosting an exclusive, invite-only reception on June 3 — the eve of BioCentury's Grand Rounds conference — gathering top voices in biotech innovation and investment to exchange bold ideas, spark new collaborations and channel the energy of Chicago's thriving innovation ecosystem. If you're interested in attending, please register here. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/655964#biotech #biopharma #pharma #lifescience #politics #policy #law00:01 - Sponsor Message: Jeito Capital05:05 - European Biotech's Moment?19:00 - Boston Pharma, Biomarin Deals29:41 - Novo Nordisk CEOTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering: Stretching yourself by tapping into the collective wisdom of others The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin). He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sage has rejected Biogen's unsolicited buyout offer and will seek strategic alternatives. Biogen and Eisai have received approval for a monthly maintenance regimen for Alzheimer's drug Leqembi. Veru's drug has shown promise in sparing lean mass in overweight adults on Wegovy. The Duchenne muscular dystrophy space is on the verge of a pivotal era with several companies developing investigational therapies. Akero has rebounded in a mid-stage trial, Daiichi Sankyo is optimistic for 2025, and Allakos is cutting its workforce. The text discusses the advancements in the Duchenne Muscular Dystrophy (DMD) space as it enters a pivotal era, with companies such as Capricor Therapeutics, Wave Life Sciences, and RegenxBio working on investigational therapies to address unmet needs. It also mentions Daiichi Sankyo's recent success with the approval of Astrazeneca-partnered Dato-DXD. Additionally, new treatments are in development for Achondroplasia to challenge Biomarin's Voxzogo. Novo's obesity drug shows promising results, Merck's Keytruda combo fails in a Phase III trial for GI cancer, and Tris Pharma wins late-stage for a non-opioid painkiller. The text also invites feedback from readers on topics they would like to see covered in the future.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Eli Lilly experienced lower-than-expected sales for its weight loss and diabetes drugs in the third quarter, causing its stock to drop by over 13%. Biogen, on the other hand, exceeded expectations for its Alzheimer's drug Leqembi. Biomarin surpassed sales estimates for its drug Voxzogo, while Sage reported revenue growth for Zurzuvae. Biogen also signed a deal with Neomorph. Additionally, Lilly has modified the dosing of its Alzheimer's drug Kisunlan to lower brain swelling, and Novartis has secured expansion for its CML drug Scemblix. Small funds are investing in early-stage science, and there have been recent job openings in the biotech industry.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über Chinas Konjunkturpaket, Donald Trumps Attacke auf die deutschen Autobauer und die Monopolklage gegen Visa. Außerdem geht es um Nvidia, Estée Lauder, LVMH, Kering BMW, Volkswagen, Mercedes, Porsche, Commerzbank, Mastercard, Alibaba, JD.com, BYD, NIO, ishares Core S&P 500 ETF (WKN: A0YEDG), SPDR S&P U.S. Utilities Select Sector ETF (WKN: A14QB6), NextEra Energy, The Southern, L&G E-Commerce Logistics ETF (WKN: A2H5GL), Walmart, Alibaba, eBay, DHL, Kühne&Nagel, DSV, FedEx, Duke Energy, Constellation Energy, L&G Russell 2000 US Small Cap Quality ETF (WKN: A0Q8H2), Hamilton Lane, Hims&Hers Health, Abercrombie&Fitch, HAN-GINS Tech Megatrend ETF (WKN: A2JR0J), TeraWulf, Snap, Grindr, Nvidia, Dell, Invesco NASDAQ Biotech ETF (WKN: A12CCJ), Vertex, Moderna, Biomarin, Illumina, EUWAX Gold II ETC (WKN: EWG2LD) und iShares Core MSCI EM IMI ETF (WKN: A2JDYF). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Delays in clinical trials can cost up to $8 million per day, making it crucial to understand and address the main factors causing these setbacks. Strategies to keep clinical trials on schedule include identifying common issues that slow down studies, addressing challenges effectively to minimize risks, and understanding potential financial losses to avoid them. By taking control of clinical trial timelines, researchers can prevent costly delays and ensure successful completion of studies.Senseonics has received FDA clearance for a continuous glucose monitoring (CGM) device that can be worn for up to 365 days. Boston Scientific has closed its acquisition of Silk Road Medical, while Smiths Medical has recalled airway tubes due to a defect that has caused more than 10 injuries. Medtech firms have cut over 14,000 jobs in the past 18 months. Exact Sciences has announced that data supports its colon cancer blood test, which could compete with Guardant Health's similar test. Bausch + Lomb is considering a sale, with private equity firms being potential buyers. The wearables market is expected to grow by 13% annually between 2024 and 2030.Merck's ADC data shows promising results in a lung cancer trial, while Ascendis' trial data puts pressure on Biomarin. Nura Bio secures $68 million in funding for neuroprotective brain drugs. The Biosecure bill could lead to drugmakers pivoting towards China. ESMO24 highlights include a cancer cachexia drug and the impact of immunotherapy on survival rates. Drug development leaders are turning to AI to drive efficiency.Cigna is suing the FTC over a report on pharmacy benefit managers, while employer health costs are expected to rise by 5.8% per employee in 2025. Johns Hopkins has appointed a new cybersecurity chief, and healthcare worker strikes are being tracked, such as nurses at Brigham and Women's Faulkner Hospital planning a strike. Employers are making cost-cutting changes to health plans, and the impact of mentorship in healthcare is highlighted.Pizza Hut is using its pizza boxes to help job seekers get noticed by putting resumes on them. Frito-Lay's campaign targeted at Gen Zers encourages fans to cheat on Flamin' Hot Cheetos with other brands. The US ad spending rebound is proving to be robust beyond cyclical events, such as the Olympics. However, customers don't trust AI, which could be hurting businesses as it decreases purchasing intention.The pharmaceutical industry is facing challenges in expanding patient access and improving cancer research outcomes. Compassionate use, also known as expanded access, provides unapproved drugs to terminally ill patients as a last resort. Radiopharmaceuticals have seen a resurgence in activity and interest from big pharma for treating cancer. Ratio Therapeutics advocates for compassionate use due to the low-risk, high-reward nature of radiopharmaceuticals. Despite challenges like patient safety and ongoing clinical trials, radiopharmaceuticals are gaining momentum in the industry. Big pharma companies are embracing this trend, with smaller players also making waves in the market. The industry is exploring strategies for better site selection in clinical trials and enhancing efficiency during gene therapy development.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. This week's commercialization news includes Dupixent's success in a chronic hives study, Lilly's development of a weekly insulin shot, and BioMarin's plans for growth. The House backs a bill restricting China's role in US biotech, while Lykos CEO is set to depart after FDA rejection and layoffs. The newsletter also discusses key developments in cell therapy and offers insights on utilizing a direct-to-patient model in the healthcare industry. Various resources and upcoming events in the biopharma industry are also highlighted. Biopharma Dive provides in-depth journalism and insights into the latest news and trends shaping the biotech and pharma industries.BridgeBio has reduced its gene therapy budget after data from a trial on an adrenal gland medicine did not meet the company's investment threshold. GlaxoSmithKline has discontinued a herpes vaccine after it did not meet efficacy goals in a phase 2 study. Roivant has launched a new 'vant' focused on a hypertension drug. Centessa's sleepiness drug has shown promising results in early studies, leading to a rise in the company's shares. Additionally, Dupixent has succeeded in a chronic hives study, giving Sanofi and Regeneron a chance to resubmit their application for approval. Investors are also paying attention to Centessa's sleepiness drug. This news comes alongside updates on other pharmaceutical developments, such as Saxenda's effectiveness for children as young as 6 and Roche's expansion of R&D labs. Additionally, the newsletter covers upcoming events and resources for biopharma professionals. Biopharma Dive provides in-depth coverage of news and trends in the biotech and pharma industries, including clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.Iowa has awarded Centene's subsidiary, Iowa Total Care, a Medicaid managed care contract worth $2.8 billion. Telehealth groups are urging Congress and the White House to extend controlled substance virtual prescribing before pandemic-era flexibilities expire. The Biden administration has finalized a rule raising mental health coverage standards for private plans. Steward Health Care received court approval to sell its three most valuable hospitals to Orlando Health for $439 million. The importance of data quality in realizing value from medical imaging data is emphasized by Enlitic. Payers are encouraged to optimize quality and grow revenue through key strategies in an upcoming webinar. Healthcare Dive provides in-depth journalism and insight into the most impactful news and trends shaping healthcare across various sectors like health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.Novo Nordisk showcased its investigational GLP-1 pill that resulted in a remarkable 13% weight loss. This comes after positive Phase I results for the pill, which analysts compared to weight loss pills being developed by Lilly and Pfizer. Expanded coverage for cardiovascular disease under Medicare could have significant implications for Novo's obesity drug, Wegovy. Analysts estimate that the expansion of Wegovy's label beyond obesity could lead to an annual Medicare spending of $145 billion. Meanwhile, GSK has abandoned the development of its herpes vaccine after disappointing Phase I/II results, and Crispr Therapeutics and Vertex Pharmaceuticals are facing challenges in making their sickle cell gene therapy profitable. Novo's other drug, Saxenda, was found to effectively and safely lower BMI in children, according to a study published in NEJM. Additionally, Lilly continues to make progress with its once-weekly insulin, while Bain has raised $3 billion for a fund supporting life sciences companies. The biopharmaceutical industry continues to see changes, with Biomarin facing challenges and Terns moving forward in the obesity spac

Summit Therapeutics made headlines this weekend at the 2024 World Conference on Lung Cancer, revealing that its bispecific antibody outperformed Keytruda in first-line non-small cell lung cancer. Meanwhile, bispecifics are one of several therapeutic classes on the agenda at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona later this week. Last week, BioMarin held a public address intended to calm anxious investors after rounds of layoffs and pipeline changes—but many were left wanting. Also undergoing major upheaval is Lykos Therapeutics, which laid off 75% of its workforce after failing to secure approval for its MDMA-based post-traumatic stress disorder therapy and announced last week that CEO Amy Emerson is stepping down from her role. In Washington, D.C., Congress is back in session this week and wasted no time in reviewing the BIOSECURE Act, which passed a House vote on Monday.  And on the weight loss front, Terns Pharmaceuticals is moving ahead to Phase II after its investigational GLP-1 pill elicited positive results in Phase I, and Amgen is pushing MariTide into a broad late-stage development program that will test the obesity treatment in other weight-related conditions, such as heart, kidney and liver diseases.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Biopharma company ArsenalBio recently raised $325 million in funding, marking one of the largest biotech funding rounds of the year. This news comes as Biomarin focuses on growth plans centered around their drug for skeletal disorders. However, the gene and cell therapy investment market is currently experiencing a slowdown, with fewer funding rounds closed compared to previous years. On a positive note, a high-dose study of Biogen's spinal muscular atrophy drug showed promising results, while Denali Therapeutics and Regenxbio are moving forward with drug approval applications. In the oncology research sector, advancements in treatments, particularly in cancer immunotherapy and personalized medicine based on genetics, continue to be made. Despite these successes, there are reports of challenges faced by gene therapy companies, such as the closure of Astellas Gene Therapies' manufacturing facility affecting 100 employees and employers hesitant to cover the costs of rare disease treatments.The EU GMP Annex 1 revision has significant impacts on drug manufacturers, as non-compliance puts their ability to create and sell products in impacted markets at risk. Manufacturers must assess components for readiness to comply with the new regulations to avoid manufacturing non-compliance, potential product recalls, and market exclusions. To maintain compliance, staying informed about key considerations and taking steps to mitigate risks is crucial.Mississippi has awarded medicaid contracts to Centene, Molina, and TrueCare. Steward Health Care faced financial challenges with unprofitable deals in Massachusetts, while CEO Ralph de la Torre snubbed a Senate subpoena. Molina appointed its CFO to oversee its medicaid and ACA marketplace businesses. Healthcare providers are addressing burnout among staff, trends in telehealth and provider-payer relationships are being discussed. In California, the Senate passed a bill to regulate private-equity healthcare deals while a judge blocked Ohio from enforcing laws restricting medication abortions.Edwards recently laid off more than 500 employees after selling its critical care division to BD. The FDA has issued warning letters to four companies regarding ozone cleaners for CPAP machines. Abbott has partnered with Beta Bionics to integrate its glucose sensor with an automated insulin delivery system. The European Heart Group recommends renal denervation for some patients with uncontrolled high blood pressure.Biopharma Dive's newsletter on September 5, 2024, highlighted various key topics in the biopharma industry focusing on industry trends and developments. Additionally, it featured sponsored content on AI's role in life sciences and white papers on process analytical technology in the biopharma industry.The pharmaceutical industry faces challenges in reputation and communication with the media despite recent successes such as the development of COVID-19 vaccines. Merck & Co.'s Chief Communications and Public Affairs Officer is promoting openness and transparency in communication to improve the industry's reputation.Cell and gene therapy research is gaining interest from investors and innovators despite facing challenges in keeping up with industry growth. The latest developments focus on overcoming barriers with outside support and potential advancements in CAR-T cell therapy options.Payers can strategically use technology to build a solid data foundation by improving provider data quality through new technology tools.Researchers need to effectively collect social determinants of health (SDoH) data while ensuring privacy and security. A playbook provides insights on utilizing SDoH data effectively for health economics & outcomes research.Industry professionals are invited to join Snowflake Industry Day, a virtual event focusing on how technology leaders use

Eli Lilly shook up the weight loss market again last week, announcing plans to sell single-dose vials of its blockbuster GLP-1 drug Zepbound directly to consumers. Meanwhile, Novo Nordisk said Monday that it expects the shortage for the lower doses of its own GLP-1 therapy Ozempic to persist into the fourth quarter of 2024. This week, we take a closer look at eyes, where gene therapy is breaking through against wet AMD, a common cause of blindness—potentially significantly minimizing the number of treatments required by patients—and cell therapy is making strides against another common foe: dry eye disease. Lastly, an unfortunate trend—layoffs—continues to play out, with BioMarin, Genentech and Astellas Gene Therapies all parting with staff members. 

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA approves Illumina cancer biomarker test  The bad — BioMarin reveals more layoffs  The ugly — FDA hits API maker Global Calcium with 483 

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medtronic's chief medical officer of acute care and monitoring has departed for a new role. The FDA has finalized voluntary malfunction summary reporting guidance. Penumbra is laying off 71 people after axing its virtual reality division. Qiagen and AstraZeneca have expanded their companion diagnostic pact. The Association for Molecular Pathology is suing to block an FDA lab test rule. Layoffs in the medical device industry continue to be a trend. Industry news includes the launch of the first over-the-counter glucose monitor, unexpected partnerships in diabetes tech, and pushback on FDA regulation of lab-developed tests.The text discusses various updates in the biopharma industry, including Alnylam's heart drug data sparking debate, Novo building a heart failure case for semaglutide, and a slump in cell and gene therapy investment. The industry is shifting towards more patient-centric commercialization strategies, with companies like Pfizer and Lilly breaking into the direct-to-consumer market. The summer has been a mixed bag for biotech, with market fluctuations and limited IPOs and acquisitions. Alnylam's full study data on its heart drug vutrisiran showed benefits but also raised skepticism. Novo's analysis showed semaglutide's effectiveness in reducing heart failure risk. Additionally, PBM executives are facing fines for alleged perjury in a house hearing defending their business practices.The text discusses the pricing and sales of gene therapies, particularly focusing on Novartis' Zolgensma, which has been the only gene therapy to cross the blockbuster threshold with sales of $1.2 billion in 2021 and $1.4 billion in 2022. While high price tags have not always resulted in significant returns for pharmaceutical companies with gene therapies, Zolgensma has been an exception. Other companies have faced challenges with new gene therapies, such as Biomarin Pharmaceuticals, which recently announced layoffs due to dismal sales of its hemophilia A gene therapy Roctavian.Alnylam Pharmaceuticals has released detailed data on their drug Vutrisiran, showing its benefits in treating a progressive and fatal heart condition known as ATTR cardiomyopathy. The results were published in the New England Journal of Medicine. While the data confirms the therapy's benefit, there are still questions about how exactly Vutrisiran should be used in treating the disease. The study is expected to continue to fuel debate among doctors.The text discusses the recent slump in investment in cell and gene therapy, with fewer venture funding rounds closed by developers in the first six months of 2024. Two companies, Biomarin and Tome Biosciences, are cutting jobs, with over 200 and over 100 layoffs respectively. Biomarin has made changes to its executive team and drug pipeline to refocus resources. Additionally, Bayer has partnered with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. The text also highlights the challenges faced in clinical trials, with nearly 80% failing to meet enrollment goals and schedules. The importance of understanding social determinants of health for research is emphasized.Biopharma Dive's Gene Therapy Weekly provides news and insights on gene therapy for biopharma leaders.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Clinical trials often fail to meet their enrollment goals and schedules, leading to significant financial losses. A new playbook offers solutions to address common challenges in clinical trial recruitment, including strategies for identifying additional participants, engaging and empowering individuals, and refining protocol criteria. The playbook provides insights on how to rescue trials when misalignment occurs, aiming to help brands in the biopharma industry tell compelling stories, build trust, and drive demand.Penumbra has decided to exit the virtual reality business, resulting in the layoff of 71 employees, as the company shifts its focus back to its core thrombectomy business. Qiagen and AstraZeneca have expanded their companion diagnostic partnership beyond cancer, allowing specialty care providers to perform genotyping during routine clinical examinations. Illumina has received FDA approval for a companion diagnostic cancer test that can identify patients eligible for treatment with specific medications targeting genetic features. Johns Hopkins, CareFirst, and Techstars have launched a healthcare AI accelerator program to support up to 12 startups working on AI tools. Medical sales teams are increasingly investing in training and skills development to adopt a more human-centered approach to sales.Biopharmaceutical company BioMarin has announced its second round of layoffs this year, with 225 employees globally being let go. This comes after changes to the company's C-suite last week and a previous round of 170 job cuts in May. In other news, Novartis is expanding its Sirna therapy Leqvio after successful Phase III study results, while Merck has ended two late-stage studies of Keytruda due to disappointing data. Regeneron is suing Sandoz in federal court to block a biosimilar of its drug Eylea. The pharma industry continues to see changes and challenges, with companies making strategic decisions based on clinical trial results and market conditions.Cognition Therapeutics, a small biotech company, recently announced positive results from a mid-stage Alzheimer's study. However, despite the promising results, the company's share price plummeted, puzzling many. The conflicting narratives surrounding the study highlight the significance of presenting scientific results in a way that reassures investors about the risks involved. The success of clinical trials is crucial for small biotechs in the competitive field of Alzheimer's research. Investor support is essential for advancing treatments for Alzheimer's, as progress cannot be made without adequate funding.The Health and Human Services (HHS) plans to appeal a lawsuit decision regarding online tracking technology. The Northwell-Nuvance merger has been approved by state attorneys general with certain conditions, while McLaren Health Care has restored its network after a ransomware attack. The shortage of mental health providers is being addressed with digital tools, and efforts to combat burnout in healthcare are ongoing.Neurocrine's mixed schizophrenia data disappoint Wall Street despite "positive" results, leading to a 20% slide in shares. The FDA rejection of the first MDMA therapy signals challenges in the psychedelic drug field. Bayer partners with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. A study suggests that covering Wegovy for heart risk could cost Medicare tens of billions each year.Pfizer has partnered with Flagship's Quotient to utilize genetics in targeting heart and kidney diseases. Moderna is facing tough competition as it tries to determine its next move in the biopharmaceutical industry. Neurocrine Biosciences saw a drop in shares despite meeting the primary endpoint in a mid-stage schizophrenia trial.Lykos Therapeutics faced a setback when the FDA rejected its MDMA therapy for PTSD and laun

Audio roundup of selected biopharma industry content from Scrip over the business week ended 23 August 2024. In this episode: CMS's price reveal better than expected?; new diabetes risk data for Zepbound; can J&J's lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark's shifting revenues. https://scrip.citeline.com/SC150795/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Steward Health is closing two Ohio hospitals and a Pennsylvania facility due to financial reasons, drawing criticism from healthcare workers and unions. McLaren Health Care in Michigan is facing disruptions from a ransomware attack, while Humana has settled whistleblower allegations of Medicare Part D fraud for $90 million. A judge has struck down an FTC ban on noncompete agreements nationwide, impacting the healthcare industry. Massachusetts has brokered agreements for Steward to sell five hospitals as part of bankruptcy proceedings. The healthcare industry is focusing on delivering patient-centric experiences and combating burnout. Recent articles cover topics such as medical tourism, health care fights, private equity deals, and reproductive freedom. As Bristol Myers' schizophrenia drug nears approval, AbbVie and other competitors are looking to enter the market with new antipsychotics to improve patient adherence. BridgeBio is sending rare disease drugs to a new company called GondolaBio, backed by $300 million from investors. Regeneron faces FDA delays for a myeloma drug due to manufacturing issues. Biomarin has reshuffled its executive team with new heads of R&D and business development. Lilly's tirzepatide has shown promising results in reducing the risk of type 2 diabetes progression. Drugmakers are strategizing for upcoming patent expirations by finding new products and markets. Edwards Lifesciences is continuing its mergers and acquisitions spree by acquiring Genesis MedTech's TAVR technology and investing $25 million in the company. In other news, Johnson & Johnson is buying heart failure implant maker V-Wave for up to $1.7 billion, while Medtronic asserts that its diabetes strategy remains unchanged despite a partnership with Abbott. The FDA defends Jeff Shuren's tenure amid ethics concerns, Dupont acquires Donatelle Plastics for $313 million, and a survey reveals that small biopharma and CROs are increasingly using multiple trial technologies. Steward Hospitals is closing two facilities in Ohio and one in Pennsylvania due to financial reasons. Dissatisfaction with electronic health records (EHR) is increasing nurses' burnout risk, with a third of nurses attributing their burnout symptoms to EHR issues. Updated COVID-19 vaccines from Pfizer and Moderna have been approved by the FDA to better match current virus strains. The Center for Medicare & Medicaid Services (CMS) has received 12,000 complaints of noncompliance with surprise billing regulations and has won $1.7 million in restitution.The ongoing struggle for health equity in the pharmaceutical industry highlights disparities in cancer treatment access and outcomes. Efforts to improve outcomes for black cancer patients through increased screening rates have not been successful, with income disparity playing a significant role in cancer rates among different backgrounds. Various industry leaders and experts share insights on strategies to improve diversity in clinical trials, tackle health disparities, and promote health equity.This week in gene therapy news, Biomarin has reshuffled its C-suite with new executives from Amgen and Roche, while Avidity and Kymera have raised fresh funds. Zealand and Arrowhead are advancing obesity drugs, while Bluebird has narrowed its launch guidance. The rise of antibody-drug conjugates in cancer treatments is discussed along with upcoming events in the biopharma industry.For more updates on gene therapy, subscribe to Biopharma Dive's newsletter.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Leqembi, a new biotech drug, has been approved in the UK, but reimbursement may not follow due to concerns about the cost to the NHS. The FDA defended its med device chief's tenure after ethics concerns were raised. Employers are expecting higher health costs next year, driven by rising pharmacy spending on drugs like GLP-1 for obesity. BridgeBio has sent rare disease drugs to a new company called GondolaBio, backed by investors including Viking Global Investors and Sequoia Capital. Versant has launched a new startup called Borealis Biosciences with funding from Novartis.New Jersey has announced plans to erase $100 million in medical debt for nearly 50,000 residents, following similar initiatives by other states and federal regulators. Molina Healthcare has extended CEO Joe Zubretsky's contract through 2027, along with a stock grant potentially worth $51 million. Additionally, CMS has received 12,000 complaints of noncompliance with the No Surprises Act, resulting in $1.7 million in restitution.Novartis and Versant have launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases, following the success of Chinook Therapeutics. Meanwhile, Wuxi Biologics reported a 24% drop in net profit in the first half of 2024 despite signing a record number of new projects. In other news, Biogen and Eisai's Alzheimer's drug Leqvembi has been approved in the UK but deemed too expensive by NICE, while Biomarin has brought on Roche and Amgen alums in an executive restructuring.The text discusses the potential impact of the Democrats' proposed changes to Medicare drug price negotiations on the pharmaceutical industry's research and development (R&D) efforts. Kamala Harris is expected to address these issues during the Democratic National Convention, with the party aiming to lower drug prices by increasing the number of drugs subject to negotiations.TE Connectivity offers sensor solutions for minimally invasive devices, providing precision and safety for procedures such as cardiac mapping and ablation. Their sensor technology can enhance efficacy in heart arrhythmia treatments. The comprehensive sensor solutions guide provides detailed applications, key features, and benefits of their sensors.The text discusses the importance of collecting and using social determinants of health (SDOH) data in health economics and outcomes research (HEOR). It highlights the challenges of collecting SDOH data and provides insights on how to effectively use the data while ensuring privacy and security. The text emphasizes the significance of diverse and inclusive research practices, evaluating data validity and sourcing, and effectively utilizing SDOH data to gain more accurate insights in HEOR.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biopharma news on August 21, 2024 saw changes in Biomarin's C-suite, with Greg Friberg and James Sabry taking over R&D and business development. BridgeBio launched GondolaBio for rare disease drug programs, while Regeneron faced FDA setbacks for a myeloma drug. Avidity and Kymera raised funds, Walgreens partnered with Barda, and Merck licensed an antibody drug conjugate. Thermo Fisher Scientific supported oncology research with new developments in clinical trials. Overall, the industry saw leadership changes, setbacks in drug approvals, fundraising activities, partnerships, and innovations in clinical trials.A study suggested that patients on Novo Nordisk's semaglutide may have a higher risk of suicidal thoughts. The FDA denied Regeneron's drug approval for myeloma due to manufacturing issues. Lawmakers raised concerns about US biopharma companies working with the Chinese military. Novo Nordisk, Eli Lilly, and Sanofi are each focusing on different markets for their diabetes GLP-1 drugs. The impact of recent Supreme Court decisions on the healthcare and pharma industries is discussed, including challenges against regulations and reforms proposed by President Joe Biden. The uncertainty could jeopardize FDA authority and provisions in the Inflation Reduction Act, adding complexity for pharma companies.The Biosecure Act revealed gaps in domestic drug manufacturing readiness in the US. Different strategies of Novo Nordisk, Eli Lilly, and Sanofi in developing and distributing their GLP-1 drugs were highlighted. A gene therapy patent ruling raised intellectual property concerns, Genentech closed its cancer immunology group, and layoffs were reported in the industry. House lawmakers expressed worries about US biopharma companies collaborating with the Chinese military on trials. Aadi Bioscience plans to lay off 80% of its R&D staff.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.This week in biopharma news, Novo's stock experienced a sell-off due to lower-than-expected obesity drug sales, Madrigal's new drug launch exceeded expectations, and Biomarin is focusing on narrowing its sales focus for its hemophilia gene therapy. Amgen discussed the differentiation of their obesity drug, Servier's brain cancer drug was approved by the FDA, and RSV vaccine makers remain optimistic despite CDC guidance. The rise of antibody-drug conjugates in cancer treatments is also highlighted.Medtronic has partnered with Abbott to develop a glucose sensor that can only connect with Medtronic's insulin delivery technology. Medtronic has also issued a recall for a nerve monitoring system linked to 10 injuries, warning users that the device may not alert when on a nerve during surgery. Henry Schein is facing slow recovery from a cyber incident, impacting their Q2 results. Ascensia's new head of CGM is planning a 365-day sensor, seeking FDA approval for a one-year sensor. The FDA is seeking feedback on health equity for medical devices, aiming to develop a framework for evaluating devices in diverse populations. Sales teams in healthcare are focusing on human-centered sales approaches.CVS has ousted the head of Aetna as the insurer's results are dragging down earnings. Premiums for ACA plans are expected to grow by 7% next year, with reasons cited including workforce shortages, hospital consolidation, and demand for expensive drugs. More than 700 rural hospitals are at risk of closing due to reimbursement challenges. Experts are concerned about patient harm from the FDA's lab developed test rule. The healthcare industry is leveraging technology such as virtual reality, robotics, and AI to improve patient engagement, staff burnout, and clinical decision-making.Madrigal's new drug launch, Rezdiffra, exceeded analysts' expectations in the U.S. prompting the company to market it in Europe independently. Novo's shares dropped after lower-than-expected sales of their obesity drugs, causing a significant loss in market value. Amgen discussed their obesity drug Maritide and its competitive profile, while Servier received FDA approval for their brain cancer drug. Biotech M&A activity is increasing, with Danish drugmaker Pharmacosmos Group acquiring G1 Therapeutics for $405 million. Despite CDC guidance affecting RSV vaccine makers, companies like GSK, Pfizer, and Moderna remain optimistic about the market.The text discusses the increasing attention on mental health and depression, particularly in the context of high-profile athletes like Noah Lyles speaking out about their struggles. Depression affects millions of people in the U.S., with many taking antidepressant medication. The text also highlights two biotech companies, Autobahn Therapeutics and Arialys Therapeutics, working on novel treatments for depression and autoimmune diseases that impact the brain, respectively. Autobahn Therapeutics recently secured significant funding to advance their depression drug into mid-stage studies.Novo Nordisk's stock dropped over 7% as sales of its semaglutide brands fell short of analyst expectations due to supply headwinds. The company also lowered its full-year profit guidance. Meanwhile, Amgen reported strong growth in the second quarter, Servier received FDA approval for a targeted therapy, and the pharmaceutical industry is hedging campaign contribution bets as the election nears. Intellia Therapeutics is working on potentially curative genome editing treatments.As the election approaches, lobbying groups and individuals from the pharmaceutical industry are supporting candidates from both parties, focusing on the future of programs like the 340b discount program and pharmacy benefit managers. Merck's distribution issue of Support the Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Small biopharma and contract research organizations are increasingly adopting eClinical technology to keep up with regulatory and market demands for research innovation. They are paying attention to how these tools can help throughout the study lifecycle. The survey report explores 11 types of clinical trial technology and when they are used, as well as the challenges to tech adoption and how vendors can assist. The report also discusses optimism for the future and emphasizes the importance of data reliability.The Southern Blood Center is recovering from a ransomware attack, causing them to implement manual processing methods for blood. The 5th Circuit Court handed providers a legal victory in the no surprises litigation, vacating instructions that advantaged insurers. Tenet is selling a majority stake in five Alabama hospitals for $910 million to pay down debt and focus on ambulatory surgery centers. Healthcare industry trends include the use of virtual reality, robotics, and AI to improve patient engagement and clinical decision-making. Healthcare data breaches are on the rise, with an Arkansas-based provider exposing the information of over 375,000 people.Biotech entrepreneur Arie Belldegrun has launched a new 'science-first' credit firm called Symbiotic Capital with $600 million in committed capital. Roche has licensed Sangamo's technology for another shot at developing an Alzheimer's drug by repressing the gene that produces the protein tau. Biomarin is reducing spending on its hemophilia gene therapy, Roctavian, and focusing sales in the U.S., Italy, and Germany. Biotech startup Red Queen has received $55 million in funding to develop versatile antivirals, including a COVID treatment.Sangamo Therapeutics has secured an exclusive licensing agreement with Genentech, a subsidiary of Roche, to develop novel genomic medicines for neurodegenerative diseases. Genentech will pay Sangamo $50 million in upfront fees and milestone payments as part of the potential $1.9 billion deal. In other news, Biomarin Pharmaceuticals is narrowing the focus of its hemophilia A gene therapy, Roctavian, to the U.S., Germany, and Italy in an effort to reduce costs and increase profitability by 2025.Pharma giants Pfizer, GSK, and Moderna are gearing up for the respiratory syncytial virus (RSV) season, which typically starts in the fall and peaks in the winter. RSV can be dangerous for infants and older individuals, leading to hospitalization and death. The FDA has approved three vaccines for RSV, but vaccination rates among adults over 60 are low.This week in biotech news, Jim Wilson, a prominent gene therapy researcher, is leaving UPenn to start two new spinouts. Otsuka has acquired startup Jnana in an $800 million deal, adding to the recent uptick in private biotech M&A. Biotech startup Airna has raised $60 million for RNA editing medicines, while 23andMe's board has rejected CEO Wojcicki's take-private proposal. Additionally, Biotech Red Queen has launched with $55 million to develop versatile antivirals.Stay informed with Biopharma Dive for all your biotech and pharma news needs!Support the Show.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  The good —  FDA approves Amgen T-cell engager for small cell lung cancer  The bad — BioMarin announces 170 layoffs  The ugly — FDA delays review of Ascendis hypoparathyroidism drug

Bone Health, Fractures, and Updates on Treatments for Bone Disorders   CME Link:           https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10095736   In this episode of "Pediatrics Now", expert pediatric endocrinologist, Dr. Nadia Merchant from Children's Health UT Southwestern, embarks on an enlightening journey into the fascinating world of bone health in children. She delves into significant bone diseases like rickets, calcium disorders, osteoporosis, and skeletal dysplasia. The episode features a balanced mix of medical insights and practical tips on maintaining bone health, specifically for children with disabilities and other chronic issues. Incorporating themes of nutrition, physical activity, and optimized genetics, the podcast also tackles the sensitive issue of child physical abuse, emphasizing the implications of bone fractures. We also explore therapeutic interventions for inherited bone disorders such as X-linked hypophosphatemia, and the role of physical activity in building stronger bones. This episode further discusses management approaches for bone health and takes a deeper dive into skeletal disorders and the world of treatments for metabolic bone disorders. Dr. Merchant concludes the episode with a Q&A session answering listener queries about premature births, DEXA scans, toddler fractures, and much more. Join host Holly Wayment for an enlightening discussion that intertwines medical knowledge with practical advice to increase awareness and improve bone health in children.   Bone Health, Fractures, and Updates on Treatments for Bone Disorders   FACULTY: Nadia Merchant, MD is a pediatric endocrinologist and geneticist at Children's Heath/UT Southwestern Medical Center.   OVERVIEW: In this podcast episode, Host Holly Wayment brings a talk from Dr. Nadia Merchant about bone health, fractures, and updates on treatments for bone disorders.   DISCLOSURES: Nadia Merchant, MD has disclosed she was a consultant/advisor for Pfizer, BioMarin, and Ascendis. The relevant financial relationships noted for Dr. Merchant have been mitigated.   The Pediatric Grand Rounds Planning Committee (Deepak Kamat, MD, PhD, Steven Seidner, MD, Daniel Ranch, MD and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose.    The UT Health Science Center San Antonio and Deepak Kamat, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests.   CONTINUING MEDICAL EDUCATION STATEMENTS: The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.   The UT Health Science Center San Antonio designates this live activity up to a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   CREDITS: AMA PRA Category 1 Credits™ (1.00) Non-Physician Participation Credit (1.00) MOC 2 credit (1.00)    

Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by guest Christine M. Albert, MD, MPH, FHRS, Cedars-Sinai Medical Center and Marina Cerrone, MD, NYU School of Medicine to discuss how Electrocardiogram (ECG) abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD), but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD. https://www.hrsonline.org/education/TheLead https://pubmed.ncbi.nlm.nih.gov/37956651/ Host Disclosure(s): J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association Contributor Disclosure(s): C. Albert: Research: Abbott, Roche Diagnostics, St. Jude Medical, NIH, Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Element Services, Inc., Illumina, Novartis M. Cerrone: Research: American Heart Association, Honoraria/Speaking/Consulting: StrideBio, Medtronic Inc., BioMarin, Inc., Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode55

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GJM865. CME/MOC/AAPA/IPCE credit will be available until March 12, 2025.A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Faculty/PlannerMaissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Iovance has launches Amtagvi The bad — FDA rejected Theratechnologies HIV instramuscular injection The ugly — BioMarin receives a subpoena from the DOJ

Kele Belton joins as a guest on this episode of the podcast to talk about how we can communicate to lead. She also provides some great insight for women in leadership.About Kele BeltonKele Belton is a Leadership and Communication expert and the founder of The Tailored Approach. She is a former corporate trainer and coach, where she collaborated with notable companies like Bank of America, BioMarin, Facebook, and Netflix, contributing to their leadership and communication growth. Kele now empowers leaders and their intact teams to communicate confidently, navigate feedback, and have difficult conversations. She's a published author, keynote speaker, and host of the Communicate to Lead podcast. Kele specializes in leadership development, communication skills, conflict management, navigating feedback, Everything DiSC assessments and coaching, personal branding, and more.Episode SummaryWhen you communicate, it's important to understand who you are speaking to, and what your message is. Is your message communicating to that person in a way that they need to receive it?  Kele speaks about this and how important it is for messaging and your audience to align.In addition, Kele discusses how women struggle in leadership in many areas. One is having the right amount of flexibility at work which allows them to take care of any home matters. Also, Kele touches on how women can display more confidence in leadership. Kele shares her proprietary BOLD framework which stands for:Breaking Through BarriersOwning the Leadership NarrativeLeading with AuthenticityDriving Continuous ChangeKele also shares more about the DISC method and how it is an assessment that measures your personality in the following areas: dominance, influence, steadiness and conscientiousness. She also helps the listeners to understand how this method intersects with her BOLD framework and can help you lead stronger.Finally, in this episode, Kele shares a bit about introversion and how introverts can focus on using their strengths, to listen. When as an introvert, you listen, you can then lean into the relationships because you've built the relationship up front. Links and ResourcesTailored ApproachOwn Your Worth, Free GuideThank you so much for listening, stay on purpose!   Support the show

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biopharma industry is facing challenges with the rocky launch of Roctavian by Biomarin, as well as the departure of AbbVie CEO Richard Gonzalez. Frontier is making strides in developing a better KRAS drug with support from Galapagos. J&J has received EMA backing for earlier CAR-T use in multiple myeloma, and a NEJM paper explores a remarkable CAR-T result in autoimmune disease. Biosimilars are gaining traction in 2024 despite initial hurdles, reflecting an increase in market presence.Sanofi and Regeneron's Dupixent are undergoing a speedy FDA review for potential use in COPD, with a decision expected by June 27, 2024. AbbVie's success with Humira serves as a model for navigating the patent cliff, under the leadership of Richard Gonzalez. Frontier Medicines secures $80 million in Series C financing, while Blueprint's cancer drug Gavreto finds a new home at Rigel Pharmaceuticals. Bristol Myers Squibb is focusing on diverse therapeutic options for cancer treatment, leveraging advanced modalities. GSK ends its collaboration with Vir Biotechnology on anti-influenza antibodies, and Indian drugmakers explore the weight-loss market with new products. Yearlybird Health launches a $186 million venture capital fund.Despite recent staff cuts at companies like Galapagos, Adaptive, and Ring, the industry continues to offer job opportunities at companies like Amgen, Novo Nordisk, Kerecis, Life Edit, Emergent Biosolutions, and Moderna. Stay tuned for more updates on the latest developments in the biopharma industry.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QYG865. CME/MOC/NCPD/AAPA credit will be available until January 21, 2025.Calling Primary Care Partners to Action in Hypertrophic Cardiomyopathy: Shortening the Time to Diagnosis for Improved Patient Outcomes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerAnjali Tiku Owens, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for BioMarin; Bristol Myers Squibb; Cytokinetics; Edgewise Therapeutics; Lexicon Pharmaceuticals, Inc.; Pfizer; Renovacor, Inc.; Stealth BioTherapeutics Inc.; and Tenaya Therapeutics.Grant/Research Support from Bristol Myers Squibb.Faculty/PlannerNeil Skolnik, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Abbott; Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Idorsia Pharmaceuticals Ltd; Lilly; Novo Nordisk; Sanofi; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from AstraZeneca; GSK; and Novo Nordisk.Speaker for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Heartland Pharma; GSK; Lilly; and Teva Pharmaceuticals USA, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/YXF865. CME/MOC credit will be available until December 31, 2024.The ‘Clot' Thickens in the Hemophilia Story: Clinical Perspectives on Enhancing Outcomes With Innovative Non-Factor TherapyPenn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis activity is supported by an educational grant from Novo Nordisk, Inc.DisclosuresAmy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Speakers Bureau participant with CSL Behring; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Sanofi-Genzyme; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.Prof Pratima Chowdary, MD, FRCPATH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Bayer Corporation; BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Centessa Pharmaceuticals plc/Johnson & Johnson Services, Inc.; CSL; Freeline; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Grant/Research Support from Freeline; Novo Nordisk A/S; Pfizer; and Swedish Orphan Biovitrum AB.Speakers Bureau participant with BioMarin/Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer; Sanofi; Swedish Orphan Biovitrum AB; and Takeda Pharmaceutical Company Limited/Chugai Pharmaceutical Co., Ltd.Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.All of the relevant financial relationships listed for these individuals have been mitigated.

Good day to our listeners! In today's episode, we're bringing you several exciting updates from the world of pharma and biotech. Let's dive right in.First up, we're talking about a game-changing webinar hosted by Cytiva. They're discussing a revolutionary, scalable process for producing clinical-grade plasmid DNA. This method is not only efficient but also reduces the purification steps significantly. If you're interested in the intricacies of genomic medicines, this is something you won't want to miss.In the world of health insurance, there's a buzz about Cigna and Humana potentially merging. This could be a major shake-up for the industry, but it's not without its challenges, especially on the regulatory front. Speaking of challenges, UnitedHealth's Medicare Advantage growth for 2024 could hit a snag, and Providence is still grappling with losses despite their recovery efforts. On a brighter note, Highmark Health's insurance business is making waves with boosted earnings, though Allegheny Health's operational losses are a concern. And in a concerning update, an additional 330,000 Medicare beneficiaries might have been affected by a data breach at a federal contractor. Definitely something to keep an eye on.Now, let's shift gears to A/B testing and experimentation programs. A new report, which analyzed data from over 127,000 experiments, sheds light on why many tests don't hit statistical significance and how we can look beyond revenue to other impactful metrics. If you're into data and analytics, this report is a treasure trove of insights.Patient retention in clinical trials is another hot topic we're covering. It's becoming increasingly clear that a patient-centered approach is key to not just getting patients into trials but keeping them there. The challenges range from the impact of trial locations to the feasibility of travel for patients. It's a complex issue, but solutions like telemedicine and local trial centers could be game-changers.For those interested in oncology, there's an upcoming webinar you won't want to miss. It focuses on making cancer studies more efficient and inclusive. The talk will cover innovative strategies, including the use of real-world data and technology, to improve outcomes in oncology research.Shifting our focus to retail health, we're seeing how on-premise digital screens are transforming patient care and driving revenue growth. These screens aren't just about display; they're a strategic tool for enhancing patient experiences and boosting business performance.And lastly, let's touch on some key developments in the pharmaceutical industry. We're looking at an international tax effort impacting big pharma, the potential Cigna-Humana merger, and some exciting updates from Novartis, BioMarin, Novo Nordisk, GSK, and Regeneron and Sanofi. There's a lot happening, and it's all pointing towards an exciting future for the industry.That's all for today's episode. Thanks for joining us on Pharma and Biotech Daily. Don't forget to subscribe for the latest news and updates in the industry. Have a fantastic day!

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Biomarin's next chapter; Amgen's obesity plans; Daiichi's new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn's. https://scrip.citeline.com/SC149072/Quick-Listen-Scrips-Five-MustKnow-Things

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tim Scott, President and CEO, AustinPx. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering:  The founding story of Pharmatek, and how client centricity and ‘training the hell out of the team' contributed to the growth How the niche of being a spray drying expert led to a sale of Pharmatek to Catelent... and why he didn't last very long post-acquisition The disruptive technology and team that got Tim so excited... he came back to the ‘CDMO+' world in Austin Building traction for a game-changing technology for poorly soluble compounds to get it into 100 molecules and commercial products Tim brings more than twenty years of pharmaceutical contract development and manufacturing organization (CDMO) leadership experience. Previously, Mr. Scott was co-founder and president of Pharmatek Laboratories, a CDMO where he led the growth and ultimate sale of the company to Catalent. He currently serves on the boards of multiple organizations, including Avelas Biosciences, DTx Pharma, CONNECT, BIOCOM, and the University of California, San Diego's Dean's Advisory Council for the Division of Biological Sciences. He previously served on the board of Zacharon Pharmaceuticals (sold to BioMarin in 2014). At UC San Diego, Tim has founded or supported multiple biotech spinouts including Zacharon, TEGA therapeutics, LipoNexus, Knoubis Bio, Nerio and Augment Biosciences. Mr Scott earned his BA in Biochemistry from UC San Diego and his JD from the University of San Diego. He is a member of the California Bar. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023      CME/CE credit expires: July 24, 2026

You don't have to set your career path in stone, you can explore and create development in any number of ways. That advice comes from this week's guest Ara Hamamjian, Executive Director, Treasurer at BioMarin, a world leader in developing and commercializing first or best-in-class therapies for rare genetic diseases. With his extensive experience in treasury across various industries, Ara brings his invaluable expertise to this week's episode of The Treasury Career Corner.On the episode, Ara shares his treasury career journey, starting from his college fraternity treasurer role to working at companies like Hewlett-Packard, Levi Strauss & Co, Electronic Arts, Fitbit, and now BioMarin.He discusses the challenges and opportunities he faced in each role and highlights the importance of networking and adaptability in career development. Ara also touches on the impact of the COVID-19 pandemic on treasury operations and the value of in-person interactions in building relationships and professional growth.On the podcast we discuss… Ara's career journey from college fraternity treasurer to treasury roles at various companies The benefits of working in both large corporate and smaller treasury teams The challenges and opportunities in treasury roles at Hewlett Packard, Levi Strauss, Electronic Arts, Fitbit and BioMarinThe impact of the COVID-19 pandemic on treasury operations and shift to remote workThe importance of networking and building relationships in career developmentWhy in-person interactions are crucial for deeper understanding and better communicationYou can connect with Ara Hamamjian on LinkedIn. Are you interested in pursuing a career within Treasury?Whether you've recently graduated, or you want to search for new job opportunities to help develop your treasury career, The Treasury Recruitment Company can help you in your search for the perfect job. Find out more here. Or, send us your CV and let us help you in your next career move!If you're enjoying the show please rate and review us on whatever podcast app you listen to us on, for Apple Podcasts click here!Subscribe to the Treasury Career Corner podcast newsletter to receive a link to every week's episode as soon as it's published via click here!